Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance

BACKGROUND: Crizotinib has demonstrated favorable efficacy in patients with advanced ALK‐positive non‐small cell lung cancer (NSCLC). Unfortunately, the majority of ALK‐positive patients ultimately develop acquired resistance within one year after the initiation of crizotinib treatment; however, the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Thorac Cancer
Glavni autori: Xu, Haiyan, Yang, Guangjian, Yang, Lu, Yang, Yaning, Ma, Di, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Wang, Yan
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2019
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500969/
https://ncbi.nlm.nih.gov/pubmed/30920172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13050
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items